Compare HCA Health Inc (HCA) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Microchip Technology Inc. — how do they compare? HCA Health Inc trades at $443.69 (market cap $96.35B), while Microchip Technology Inc. trades at $76.52 (market cap $41.01B). The key difference: HCA Health Inc is far larger — about 2.3× Microchip Technology Inc.'s market cap, and Microchip Technology Inc. pays the higher dividend (2.41%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Microchip Technology Inc. for 62 Days on average.
| HCA | MCHP | |
|---|---|---|
Market Cap | $96.35B | $41.01B |
Volume | 1,079,453 | 9,972,516 |
Sector | Health | Technology |
52-Week High | $545.13 | $102.97 |
52-Week Low | $361.32 | $49.02 |
Typical Hold Time | 76 Days | 62 Days |
Enterprise Value | $146.88B | $46.13B |
Dividend Yield | 0.7% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth, reaching $75.6B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $461.12 price target, supported by solid cash flow from operations of $12.64B and a net income margin of 8.77%.
The outlook remains positive given earnings momentum and operational efficiency, but risks include ongoing legal investigations and high debt levels. Upside potential exists if the company maintains its earnings beat streak and manages payer-mix challenges effectively.
Microchip Technology (MCHP) trades at $78.02, down 3.99% on the day, amid a bearish technical signal. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue declined sharply in 2025 to $4.40B, resulting in a net loss, but 2026 projections show recovery. Analyst consensus is strongly bullish with a $110.50 price target. Recent news highlights expansion in Ethernet and power portfolios, plus the acquisition of Hailo to bolster edge AI capabilities.
MCHP's outlook is supported by robust analyst buy ratings and exposure to growing AI and data center demand. However, high valuation multiples, significant debt, and cyclical semiconductor risks pose challenges. Earnings growth in 2026 will be critical to justifying its premium valuation and driving shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
